ESR1 and uterine corpus sarcoma: This study also evaluated the prognostic significance of oestrogen receptor expression in ESS, demonstrating improved overall survival in ER-positive uterine sarcomas compared with ER-negative patients (median OS 36 vs. 16 months, p = 0.004).